Skip to main content
. 2014 Sep 19;78(4):748–762. doi: 10.1111/bcp.12387

Table 1.

Baseline characteristics of the 36 trials included in the meta-analysis (n = 10 553)

Authors/phase Histology Patients enrolled Treatment arm Number for analysis Median age (years) Median treatment duration (months) Median PFS/TTP (months) Median OS (months) Number of high grade CHF Reported events Jadad score
Demetri et al. [13]/III* GIST 312 Sunitinib 50 mg d1−1-28, q6w 202 58 1.9 6 NR 3 LVEF decline 5
Placebo 102 55 1 1.5 NR 0
Motzer et al. [15]/III* RCC 750 Sunitinib 50 mg d1−1-28, q6w 375 62 6 11 NR 13 LVEF decline 3
INF 9 MUI 3 times weekly 360 59 4 2 NR 4†
Barrios et al. [58]/III* HER-2 negative BC 482 Sunitinib 37.5 mg qd + capecitabine 1 250 mg m−2 d1–14 bid po, q3w.§ 238 53 2 2.8 15.3 1 Congestive failure 3
Capecitabine 1 250 mg m−2 d1–14 bid po, q3w 244 53 2 4.2 24.6 0
Abou-Alfa et al. [70]/II* HCC 96 Doxorubicin + sorafenib 400 mg bid po qd 47 66 4 6 13.7 1 LV dysfunction 5
Doxorubicin + placebo 49 65 1.9 2.7 6.5 0
Raymond et al. [69]/III* PNET 171 Sunitinib 37.5 mg qd po 86 56 4.6 11.4 NR 2 Cardiac failure 5
placebo 85 47 3.7 5.5 NR 0
Kindler et al. [43]/II* Pancreatic carcinoma 632 Axitinib 5 mg bid po + gemcitabine 1000 mg m−2 d 1, 8, 15 q4w. 314 61 2.8 4.4 8.5 1 Cardiac failure 5
Placebo + gemcitabine 1000 mg m−2 d1, 8, 15. q4w. 316 62 2.3 4.4 8.3 0
Bergh et al. [59]/III* MBC 593 Sunitinib 37.5 mg qd po q3w. + docetaxel 296 54 6.1 8.6 24.8 1 Cardiac failure 5
Placebo + ocetaxel 297 56 4.2 8.3 25.5 0
Mulders et al. [57]/II* RCC 71 Cediranib 45 mg qd po 53 60 12 12.1 NR 1 LVEF decline 5
placebo 18 61 NR 2.8 NR 0
Wells et al. [42]/III* Thyroid cancer 331 Vandetanib 300 mg qd po 231 50.7 21 30.5 NR 1 Cardiac failure 5
placebo 100 53.4 9.3 19.3 NR 0
van der Graaf et al. [7]/III* STS 372 Pazopanib 800 mg qd po 246 51.9 3.83 4.6 12.5 3 LVEF decline 5
placebo 123 56.7 1.89 1.6 10.7 0
Cristofanilli et al. [60]/II* Inflammatory BC 163 Pazopanib 800 mg qd po + lapatinib 1500 mg 38 52 2.8 NR 16.2 0 LVEF decline 3
Placebo + apatinib 1500 mg 38 52 3.8 NR 14.7 0
Placebo + apatinib 1500 mg 36 53 3.76 NR 15.9 0
pazopanib 400 mg qd po + lapatinib 1000 mg 38 54 2.96 NR NR 0
pazopanib 800 mg qd po 13 55 1.73 NR NR 0
Curigliano et al. [61]/II* Triple-negative BC 217 Sunitinib 37.5 mg qd po q3w. 113 52 NR 2 9.4 0 Cardiac failure 2
standard of care 104 52 NR 2.7 10.5 1
Fuchs et al. [41]/III* Gastric or gastro-oesophageal junction cancer 355 Ramucirumab 8 mg kg−1 q2w. 238 60 1.87 2.1 5.2 0 Cardiac failure 5
placebo 117 60 1.4 1.3 3.8 0
Hyams et al. [62]/II* MBC 62 Cediranib 45 mg qd po + fulvestrant 500 mg q4w. 31 NR NR 7.4 NR 0 LVEF decline 5
Placebo + ulvestrant 500 mg q4w. 31 NR NR 3.7 NR 0
Johnston et al. [63]/II* HER-2 positive BC 177 Pazopanib 400 mg qd po + lapatinib 1000 mg 69 50 NR NR NR 0 LV dysfunction 3
Placebo + lapatinib 1500 mg 72 54 NR NR NR 0
Lapatinib + pazopanib 800 mg qd po 36 54 NR NR NR 0
Motzer et al. [14]/II RCC 63 Sunitinib 50 mg d1−1-28 q6w 63 60 9 8.7 NR 1 LVEF decline NA
Motzer et al. [49]/II RCC 106 Sunitinib 50 mg d1−1-28 q6w 105 56 7.5 8.3 NR 5 LVEF decline NA
Saltz et al. [16]/II CRC 84 Sunitinib 50 mg d1−1-28 q6w, bevacizumab native 40 56.5 NR 2.3 NR 0 LVEF decline NA
Sunitinib 50 mg d1−1-28 q6w, pretreated with bevacizumab 42 57.5 NR 2.8 NR 0
Rixe et al. [50]/II RCC 52 Axitinib 5 mg bid po qd 52 59 9.4 15.7 29.9 1 LVEF decline NA
Kulke et al. [74]/II pancreatic carcinoid 107 Sunitinib 50 mg d1−1-28 q6w 107 56 12.5 7.7 16.4 1 CHF NA
Dror Michaelson et al. [72]/II prostate cancer 34 Sunitinib 50 mg d1−1-28 q6w 34 71 1.5 NR NR 1 LV dysfunction NA
Escudier et al. [9]/II RCC 107 Sunitinib 37.5 qd po 105 59 8.4 8.2 19.8 1 LVEF decline NA
Gore et al. [53]/II RCC 4564 Sunitinib 50 mg d1−1-28 q6w 4371 59 7.5 10.9 18.4 10 CHF NA
Hensley et al. [64]/II Uterine leiomyosarcoma 25 Sunitinib 50 mg d1−1-28 q6w 23 56 NR 1.54 15.1 0 LVEF decline NA
Kontovinis et al. [54]/II RCC 42 Sunitinib 50 mg d1−1-28 q6w 42 64 NR 8.9 16.23 1 LVEF decline NA
Di Lorenzo et al. [51]/II RCC 52 Sorafenib 400 mg qd po q8w. 52 60 4.1 3.73 7.5 1 LV dysfunction NA
Hoftijzer et al. [66]/II Thyroid carcinoma 31 Sorafenib 400 mg qd po q8w. 31 65 NR 13.5 NR NR CHF NA
Kloos et al. [67]/II Thyroid carcinoma 41 Sorafenib 400 mg qd po q8w. Previously treated 19 67 8.73 16 23 1 LV dysfunction NA
Sorafenib 400 mg qd po q8w. Native 22 56 9.87 10 37.5 0
Maki et al. [65]/II Sarcoma 147 Sorafenib 400 mg qd po q4w. 145 55 NR 3.2 14.3 1 Cardiac ejection fraction NA
Rini et al. [6]/II RCC 62 Axitinib 5 mg bid po qd 62 60 6.2 7.4 13.6 NR CHF NA
MacKay et al. [71]/II Cervical cancer 19 Sunitinib 50 mg d1−1-28 q6w 19 44 NR 3.5 NR 0 LV dysfunction NA
Tomita et al. [56]/II RCC 51 Sunitinib 50 mg d1−1-28 q6w 51 56.6 4.9 12.2 33.1 1 LVEF decline NA
61.1 6.5 10.6 32.5
Matsumoto et al. [68]/II GIST 18 Sunitinib 50 mg d1−1-28 q6w 18 58.7 NR 5.3 NR 0 LVEF decline NA
Hainsworth et al. [40]/II RCC 55 Pazopanib 800 mg qd po q8w. 55 60 6 7.5 NR 1 LV dysfunction NA
Kummar et al. [39]/II STS 46 Cediranib 30 mg qd po q4w. 46 27 1.87 NR NR 1 LV dysfunction NA
Reynolds et al. [73]/II NSCLC 63 Sunitinib 37.5 mg qd po q6w. 63 78.4 2.8 3 NR 0 CHF NA
*

Randomized controlled trial.

†

Data retrieved from drug package insert.

§

1200 mg m−2 in patients age ≥65 years. PFS, progression-free survival; TTP, time to progression; OS, overall survival; LVEF, left ventricular ejection fraction; CHF, congestive heart failure; RCC, renal cell cancer; STS, soft tissue sarcoma; MBC, metastatic breast cancer; NSCLC, non-small-cell lung carcinoma; GIST, gastrointestinal stromal tumours; CRC, colorectal cancer; HCC, hepatocellular carcinoma; PNET, pancreatic neuroendocrine tumours; NR, not reported; NA, not available. Qd daily; bid twice daily; q2w every 2 weeks; q3w every 3 weeks; q4w every 4 weeks; q6w every 6 weeks; q8w every 8 weeks.